Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Platelet Engraftment Failure Post-UCBT
NCT02046291Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2015
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of romiplostim in Thrombocytopenia, sponsored by Masonic Cancer Center. Primary endpoint: Maximum tolerated dose of romiplostim. Started Apr 2015; status: completed.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02046291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046291.